Takeda Pharmaceutical (TAK) Equity Income (2017 - 2026)

Takeda Pharmaceutical has reported Equity Income for 10 years, with the latest figure at $3.4 million in Q2 2026.

• On a quarterly basis, Equity Income rose 191.12% year-over-year to $3.4 million in Q2 2026; TTM through Jun 2026 was -$26.7 million, a 394.24% decrease from a year earlier, with the FY2026 full-year figure at -$13.9 million, up 46.95% from the prior year.
• Equity Income was $3.4 million for Q2 2026 at Takeda Pharmaceutical, up from -$3.2 million in the prior quarter.
• The five-year high for Equity Income was $24.3 million in Q4 2024, with the low at -$37.2 million in Q4 2023.
• Average Equity Income over 5 years is -$7.4 million, with a median of -$4.6 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Equity Income sank 241.16% in 2023, then surged 191.12% in 2026.
• Over 5 years, Equity Income stood at -$12.5 million in 2022, then sank by 197.49% to -$37.2 million in 2023, then surged by 165.41% to $24.3 million in 2024, then slumped by 121.36% to -$5.2 million in 2025, then surged by 164.93% to $3.4 million in 2026.
• The last three Equity Income figures came in at $3.4 million (Q2 2026), -$3.2 million (Q1 2026), and -$5.2 million (Q4 2025), per Business Quant data.